Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced that the company
management will participate in three upcoming virtual investor
Details of the events are as follows:
Guggenheim Healthcare Talks 2021 Oncology Day, February 11-12,
2021Adicet’s management team will participate in virtual investor
meetings at the conference on Friday, February 12, 2021.
SVB Leerink Global Healthcare Conference, February 22-26, 2021
Chen Schor, President and Chief Executive Officer, will deliver a
presentation on Wednesday, February 24, 2021 at 5:00 PM ET.
H.C. Wainwright Global Life Sciences Conference - March 9-10,
2021Registered attendees can access the recorded presentation
on-demand starting March 9, 2021 at 6:00 AM ET for the duration of
A live audio webcast of the SVB Leerink presentation can be
accessed on the Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of “off-the-shelf” gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.Investor and Media
Janhavi MohiteStern Investor Relations,